featured
Discovery of TKIs That Potently and Selectively Inhibit HER2 Exon 20 Mutants While Sparing Wild-Type EGFR in NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
Nat Cancer 2022 Jul 01;3(7)821-836, B Wilding, D Scharn, D Böse, A Baum, V Santoro, P Chetta, R Schnitzer, DA Botesteanu, C Reiser, S Kornigg, P Knesl, A Hörmann, A Köferle, M Corcokovic, S Lieb, G Scholz, J Bruchhaus, M Spina, J Balla, B Peric-Simov, J Zimmer, S Mitzner, TN Fett, A Beran, L Lamarre, T Gerstberger, D Gerlach, M Bauer, A Bergner, A Schlattl, G Bader, M Treu, H Engelhardt, S Zahn, JE Fuchs, J Zuber, P Ettmayer, M Pearson, M Petronczki, N Kraut, DB McConnell, F Solca, RA NeumüllerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.